❤️ Acute Coronary Syndrome: Reperfusion & Antithrombotics
This tool gives the reperfusion or intervention timing and the antiplatelet/anticoagulation strategy for acute coronary syndrome, separating STEMI from NSTE-ACS.
NSTE-ACS is never thrombolysed; the decision is intervention timing by risk, whereas STEMI hinges on the earliest reperfusion. (original synthesis · not guideline verbatim)
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Use to choose reperfusion in STEMI (primary PCI vs thrombolysis by time and feasibility) and intervention timing in NSTE-ACS by risk, with the antithrombotic backbone.
How it works
STEMI: primary PCI if feasible ≤ 120 min, else thrombolysis within 12 h then transfer. NSTE-ACS: no thrombolysis, intervention by risk (very-high < 2 h, high < 24 h, intermediate < 72 h, low selective). DAPT (aspirin + ticagrelor) + parenteral anticoagulant ≥ 12 months.
Key points
- NSTE-ACS is never thrombolysed; the decision is intervention timing by risk, whereas STEMI hinges on the earliest reperfusion. (original synthesis · not guideline verbatim)
- Ticagrelor is the preferred P2Y12 agent; prasugrel is limited to known coronary anatomy planned for PCI.
- Add β-blocker, statin, and ACEi/ARB unless contraindicated, and assess bleeding risk (CRUSADE).
References
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| ACS type | STEMI (ST-elevation) |
|---|---|
| Primary PCI feasible within 120 min (for STEMI) | Yes |
| Time from onset (for STEMI) | ≤ 12 h |
| NSTE-ACS risk stratification | Very high risk |
→StrategySTEMI: reperfuse as early as possible
- Reperfusion：Primary PCI (preferred; FMC-to-wire-crossing ≤ 90–120 min where possible)
- Antiplatelet：Aspirin loading 300 mg → 75–100 mg/d + P2Y12 (ticagrelor 180 mg preferred, or clopidogrel 600 mg), DAPT for at least 12 months
- Anticoagulation：Parenteral anticoagulation: unfractionated heparin or bivalirudin for primary PCI (bivalirudin favored with high bleeding risk); enoxaparin/UFH for thrombolysis
| ACS type | NSTE-ACS (NSTEMI/unstable angina) |
|---|---|
| Primary PCI feasible within 120 min (for STEMI) | No |
| Time from onset (for STEMI) | > 24 h |
| NSTE-ACS risk stratification | Low risk |
→StrategyNSTE-ACS: risk stratification defines intervention
- Intervention timing：No thrombolysis; by risk stratification: Selective intervention or non-invasive evaluation first
- Antiplatelet：Aspirin loading 300 mg → 75–100 mg/d + P2Y12 (ticagrelor preferred; prasugrel limited to known coronary anatomy planned for PCI), DAPT for at least 12 months
- Anticoagulation：Parenteral anticoagulation: fondaparinux preferred for conservative treatment; UFH or enoxaparin for planned intervention
Frequently asked questions
- What is Acute Coronary Syndrome: Reperfusion & Antithrombotics?
- This tool gives the reperfusion or intervention timing and the antiplatelet/anticoagulation strategy for acute coronary syndrome, separating STEMI from NSTE-ACS.
- How is Acute Coronary Syndrome: Reperfusion & Antithrombotics calculated? What is the core formula?
- STEMI: primary PCI if feasible ≤ 120 min, else thrombolysis within 12 h then transfer. NSTE-ACS: no thrombolysis, intervention by risk (very-high < 2 h, high < 24 h, intermediate < 72 h, low selective). DAPT (aspirin + ticagrelor) + parenteral anticoagulant ≥ 12 months.
- When is Acute Coronary Syndrome: Reperfusion & Antithrombotics used?
- Use to choose reperfusion in STEMI (primary PCI vs thrombolysis by time and feasibility) and intervention timing in NSTE-ACS by risk, with the antithrombotic backbone.
- What are the key clinical points for Acute Coronary Syndrome: Reperfusion & Antithrombotics?
- NSTE-ACS is never thrombolysed; the decision is intervention timing by risk, whereas STEMI hinges on the earliest reperfusion. (original synthesis · not guideline verbatim) Ticagrelor is the preferred P2Y12 agent; prasugrel is limited to known coronary anatomy planned for PCI. Add β-blocker, statin, and ACEi/ARB unless contraindicated, and assess bleeding risk (CRUSADE).
- What are the limits and cautions when using Acute Coronary Syndrome: Reperfusion & Antithrombotics?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is Acute Coronary Syndrome: Reperfusion & Antithrombotics calculated in practice? Can you show a worked example?
- Inputs: ACS type STEMI (ST-elevation), Primary PCI feasible within 120 min (for STEMI) Yes, Time from onset (for STEMI) ≤ 12 h, NSTE-ACS risk stratification Very high risk → Result: Strategy STEMI: reperfuse as early as possible（Reperfusion: Primary PCI (preferred; FMC-to-wire-crossing ≤ 90–120 min where possible), Antiplatelet: Aspirin loading 300 mg → 75–100 mg/d + P2Y12 (ticagrelor 180 mg preferred, or clopidogrel 600 mg), DAPT for at least 12 months, Anticoagulation: Parenteral anticoagulation: unfractionated heparin or bivalirudin for primary PCI (bivalirudin favored with high bleeding risk); enoxaparin/UFH for thrombolysis） Inputs: ACS type NSTE-ACS (NSTEMI/unstable angina), Primary PCI feasible within 120 min (for STEMI) No, Time from onset (for STEMI) > 24 h, NSTE-ACS risk stratification Low risk → Result: Strategy NSTE-ACS: risk stratification defines intervention（Intervention timing: No thrombolysis; by risk stratification: Selective intervention or non-invasive evaluation first, Antiplatelet: Aspirin loading 300 mg → 75–100 mg/d + P2Y12 (ticagrelor preferred; prasugrel limited to known coronary anatomy planned for PCI), DAPT for at least 12 months, Anticoagulation: Parenteral anticoagulation: fondaparinux preferred for conservative treatment; UFH or enoxaparin for planned intervention）